Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.

Also called NCT07077525

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 196 participants (enrolled count) (from the registry)
Sponsor
Al-Azhar University (from the registry)
Registry
  • NCT NCT07077525
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07077525. Randomized; no masking; primary purpose treatment. Start 2023-06-01 (actual); primary completion 2024-08-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors
Intervention (Combination product)
Dapagliflozin + Metformin
Intervention (Combination product)
Vildagliptin + Metformin
Lead sponsor
Al-Azhar University (class: other)
Collaborator
General Committee of Teaching Hospitals and Institutes, Egypt (class: other government)

Record details

Record id
cardio:ct-nct07077525
Content hash
6cb7c1bca31d06618a46f295c63729c56cfd4e6ac3eef91793596e89796a6f16